1998 Fiscal Year Final Research Report Summary
Monitoring method of human cytomegalovirus latent infection and viral reactivation
| Project/Area Number |
09557028
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 展開研究 |
|---|
| Research Field |
Virology
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
KONDO Kazuhiro Osaka University Medical School, Associate Professor, 医学部, 助教授 (70234929)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
AONO Toshiya Medical Research Laboratory Toyobo Research Center, Researcher, 総合研究所・メディカル研究所, 研究員
TAYA Keiko Osaka University Medical School, Associate Professor, 医学部, 助手 (80263276)
INAGI Reiko Osaka University Medical School, Associate Professor, 医学部, 助手 (50232509)
YAMANISHI Koichi Osaka University Medical School, Professor, 医学部, 教授 (10029811)
|
|---|
| Project Period (FY) |
1997 – 1998
|
| Keywords | cytomegalovirus / latency / reactivation / NASBA |
|---|
| Research Abstract |
Human cytomegalovirus (HCMV) is a significant cause of morbidity and mortality in immunocompromised patients, such as organ or bone marrow transplant (BMT), AIDS patients and developing neonates. Some antiviral drugs, such as ganciclovir and foscarnet, are useful for treating HCMV diseases, but these drugs must be used carefully because of their side effects. Therfore, it is important to establish a sensitive system by which to monitor HCMV infection.
In the diagnosis of HCMV infection, it is very important to distinguish symptomatic from asymptomatic infection. The nucleic acid sequence-based amplification (NASBA) technique was compared with single and nested polymerase chain reaction (PCR) methods.
For NASBA detection, the beta 2.7 transcript was chosen as a target because of its abundant active HCMV-specific expression. Of 20 pediatric BMT recipients, 8 developed HCMV-related clinical symptoms. The clinical sensitivities and specificities were 50% and 100% for single PCR, 100% and 67% for nested PCR, and 100% and 83% for NASBA, respectively. Follow-up of HCMV infections in pediatric BMT recipients showed that NASBA could both detect viral transcript prior to the onset of clinical symptoms and reflect clinical improvement due to antiviral therapy. These data suggest that NASBA should be useful for both predicting HCMV disease development and monitoring the effect of antiviral therapy.
|
